Cholera vaccines

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 141-152

  Clemens, John D ^a   Shin, Sunheang ^b   Sah, Binod K ^b   Sack, David A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b International Vaccine Institute   (South Korea)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902048282     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00023-9     Document Type: Chapter

References (176)

1. Carpenter C.C. Cholera: diagnosis and treatment. Bull N Y Acad Med 1971, 47:1192-1203.
2. Cholera Working Group Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 1992, 342:387-390.
3. Nair G.B., Faruque S.M., Shuiyan N.A., et al. New variants of Vibrio cholerae O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh. J Clin Microbiol 2002, 40:3296-3299.
4. Holmgren J., Lonnroth I., Ouchterlony O. Identification and characterization of cholera exotoxin in culture filtrates of V. cholerae. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1971, 79:448.
5. Mosley W.H., Ahmad S., Benenson A., et al. The relationship of vibriocidal antibody titer to susceptibility of cholera in family contacts of cholera patients. Bull World Health Organ 1968, 38:777-785.
6. Clemens J., Sack D., Harris J., et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990, 335:270-273.
7. Lucas M.E., Deen J.L., von Seidlein L., et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005, 352:757-767.
8. Sur D., Lopez A., Kanungo A., et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1694-1702.
9. Richie E.E., Punjabi N.H., Sidharta Y.Y., et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000, 18:2399-2410.
10. Ali M., Emch M., von Seidlein L., et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005, 366:44-49.
11. Cohen M.B., Giannella R.A., Bean J., et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 2002, 70:1965-1970.
12. Snow J., Frost W.H., Richardson B.W. Snow on cholera, being a reprint of two papers by John Snow 1936, Commonwealth Fund, M.D. New York.
13. Koch R. An address on cholera and its bacillus. Br Med J 1884, 2:453-459.
14. Howard-Jones N. Robert Koch and the cholera vibrio: a centenary. Br Med J (Clin Res Ed) 1984, 288:379-381.
15. World Health Organization Cholera. Wkly Epidemiol Rec 2010, 85:293-308.
16. Snyder J.D., Blake P.A. Is cholera a problem for U.S. travelers?. JAMA 1982, 247:2268-2269.
17. Mahon B.E., Mintz E.D., Greene K.D., et al. Reported cholera in the United States, 1992-1994: a reflection of global changes in cholera epidemiology. JAMA 1996, 276:307-312.
18. Carpenter C.C. Cholera: diagnosis and treatment. Bull N Y Acad Med 1971, 47:1192-1203.
19. Butler T., Arnold M., Islam M. Depletion of hepatic glycogen in the hypoglycaemia of fatal childhood diarrhoeal illnesses. Trans R Soc Trop Med Hyg 1989, 83:839-843.
20. Khan M., Shahidullah M. Cholera due to the E1 Tor biotype equals the classical biotype in severity and attack rates. J Trop Med Hyg 1980, 83:35-39.
21. Garg S., Saha P.K., Ramamurthy T., et al. Nationwide prevalence of the new epidemic strain of Vibrio cholerae O139 Bengal in India. J Infect Dis 1993, 27:108-109.
22. Cholera Working Group Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 1992, 342:387-390.
23. Morris J.G., Losonsky G.E., Johnson J.A., et al. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J Infect Dis 1995, 171:903-908.
24. Johnson J.A., Salles C.A., Panigrahi P., et al. Vibrio cholerae O139 Synonym Bengal is closely related to Vibrio cholerae El Tor but has important differences. Infect Immun 1994, 62:2108-2110.
25. Albert M.J., Alam K., Rahman A.S., et al. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J Infect Dis 1994, 169:709-710.
26. Qadri F., Svennerholm A.M., Shamsuzzaman S., et al. Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh. Infect Immun 2005, 73:6577-6583.
27. Jabeen K., Hasan R. Re-emergence of Vibrio cholerae O139 in Pakistan: report from a tertiary care hospital. J Pak Med Assoc 2003, 53:335-338.
28. Nair G.B., Faruque S.M., Shuiyan N.A., et al. New variants of Vibrio cholerae O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh. J Clin Microbiol 2002, 40:3296-3299.
29. Ansaruzzaman M., Bhuiyan N.A., Nair B.G., et al. Mozambique Cholera Vaccine Demonstration Project Coordination Group. Cholera in Mozambique, variant of Vibrio cholerae. Emerg Infect Dis 2004, 10:2057-2059.
30. Nair G., Qadri F., Holmgren J., et al. Cholera due to altered El Tor strains of Vibrio cholerae 01 in Bangladesh. J Clin Microbiol 2006, 44:4211-4213.
31. Taychoudhuri A., Patra T., Ghosh K., et al. Classical ctxB in Vibrio cholerae 01, Kolkata, India. Emerg Infect Dis 2009, 15:131-132.
32. Safa A., Sultana J., Dac Cam P., et al. Vibrio cholerae 01 hybrid El Tor strains, Asia and Africa. Emerg Infect Dis 2008, 14:987-988.
33. Siddique A., Nair G., Alam M., et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 2010, 138:347-352.
34. Wachsmuth I.K., Evins G.M., Fields P.I., et al. The molecular epidemiology of cholera in Latin America. J Infect Dis 1993, 167:621-626.
35. Cameron D.N., Khambaty F.M., Wachsmuth I.K., et al. Molecular characterization of Vibrio cholerae O1 strains by pulsed-field gel electrophoresis. J Clin Microbiol 1994, 32:1685-1690.
36. Chen F., Evins G.M., Cook W.L., et al. Genetic diversity among toxigenic and nontoxigenic Vibrio cholerae O1 isolated from the Western Hemisphere. Epidemiol Infect 1991, 107:225-233.
37. Popovic T., Bopp C., Olsvik O., et al. Epidemiologic application of a standardized ribotype scheme for Vibrio cholerae O1. J Clin Microbiol 1993, 31:2474-2482.
38. Faruque S.M., Chowdhury N., Kamruzzaman M., et al. Reemergence of epidemic Vibrio cholerae O139, Bangladesh. Emerg Infect Dis 2003, 9:1116-1122.
39. Raychoudhuri A., Mukhopadhyay A., Ramamurthy R., et al. Biotyping of Vibrio cholerae 01: time to redefine the scheme. Indian J Med Res 2008, 128:695-698.
40. Tacket C.O., Taylor R.K., Losonsky G., et al. Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection. Infect Immun 1998, 66:692-695.
41. Taylor R., Miller R., Furlong D., et al. Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci U S A 1987, 84:2833-2837.
42. Silva A., Leitch G., Camilli A., et al. Contribution of hemagglutinin/protease and motility to pathogenesis of El Tor biotype cholera. Infect Immun 2006, 74:2072-2079.
43. Butler S., Camilli A. Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat Rev Microbiol 2005, 3:611-620.
44. Lee S.H., Hava D.L., Waldor M.K., et al. Regulation and temporal expression patterns of Vibrio cholerae virulence genes during infection. Cell 1999, 99:625-634.
45. Holmgren J., Lonnroth I., Ouchterlony O. Identification and characterization of cholera exotoxin in culture filtrates of V. cholerae. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1971, 79:448.
46. Lonnroth I., Holmgren J. Subunit structure of cholera toxin. J Gen Microbiol 1973, 76:417-427.
47. Holmgren J., Lonnroth I., Svennerholm L. Fixation and inactivation of cholera toxin by GM1 ganglioside. Scand J Infect Dis 1973, 5:77-78.
48. McLeod S.M., Kimsey H.H., Davis B.M., et al. CTXphi and Vibrio cholerae: exploring a newly recognized type of phage-host cell relationship. Mol Microbiol 2005, 57:347-366.
49. Kimberg D.V., Field M., Johnson J., et al. Stimulation of intestinal mucosal adenyl cyclase by cholera enterotoxin and prostaglandins. J Clin Invest 1971, 1218-1230.
50. Holmgren J., Svennerholm A.M. Mechanisms of disease and immunity in cholera: a review. J Infect Dis 1977, 136(suppl):S105-S112.
51. Holmgren J., Svennerholm A.M. Cholera and the immune response. Prog Allergy 1983, 22:106-119.
52. Herrington D., Hall R., Losonsky G., et al. Toxin, toxin-coregulated pili, and the toxR regulon are essential to Vibrio cholerae pathogenesis in humans. J Exp Med 1988, 168:1487-1492.
53. Rollenhagen J., Kalsy A., Cerda F., et al. Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae 01 El Tor challenge in mice. Infect Immun 2006, 74:5834-5839.
54. Asaduzzaman M., Ryan E., John M., et al. The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae 01 and 0139. Infect Immun 2004, 72:4448-4454.
55. Clemens J., Sack D., Harris J., et al. Cross-protection by B subunit-killed whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988, 158:372-377.
56. Rabbani G.H., Greenough W.B. Food as a vehicle of transmission of cholera. J Diarrhoeal Dis Res 1999, 17:1-9.
57. Weber J.T., Mintz E.D., Canizares R., et al. Epidemic cholera in Ecuador: multidrug-resistance and transmission by water and seafood. Epidemiol Infect 1994, 112:1-11.
58. Rennels M.B., Levine M.M., Daya V., et al. Selective vs. nonselective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J Infect Dis 1980, 142:328-331.
59. O'Brien M., Colwell R. Modified taurocholate-tellurite-gelatin agar for improved differentiation of Vibrio species. J Clin Microbiol 1985, 22:1011-1013.
60. Harris J., Cavallaro E., de Nobrega A., et al. Field evaluation of crystal VC Rapid Dipstick test for cholera during a cholera outbreak in Guinea-Bissau. Trop Med Int Health 2009, 14:1117-1121.
61. Mukherjee P., Ghosh S., Ramamurthy T., et al. Evaluation of a rapid immunochromatographic dipstick kit for diagnosis of cholera emphasizes its outbreak utility. Jpn J Infect Dis 2010, 63:234-238.
62. Benenson A.S., Saad A., Mosley W.H. Serological studies in cholera, 2: the vibriocidal antibody response of cholera patients determined by a microtechnique. Bull World Health Organ 1968, 38:277-285.
63. Sack D.A., Sack R.B., Nair G.B., et al. Cholera. Lancet 2004, 363:223-233.
64. World Health Organization and Global Task Force on Cholera Control Guidelines for cholera control 1994, World Health Organization, Geneva.
65. Glass R.I., Huq I., Alim A.R., et al. Emergence of multiply antibiotic-resistant Vibrio cholerae in Bangladesh. J Infect Dis 1980, 142:939-942.
66. Mhalu F.S., Mmari P.W., Ijumba J. Rapid emergence of El Tor Vibrio cholerae resistant to antimicrobial agents during first six months of fourth cholera epidemic in Tanzania. Lancet 1979, 1:345-347.
67. World Health Organization Cholera vaccines: position paper. Wkly Epidemiol Rec 2010, 85:117-128.
68. Glass R., Becker S., Huq I., et al. Endemic cholera in Bangladesh, 1966-1980. Am J Epidemiol 1982, 116:959-970.
69. Clemens J., Sack D., Rao M., et al. The design and analysis of cholera vaccine trials: recent lessons from Bangladesh. Int J Epidemiol 1993, 22:724-730.
70. Clemens J.D., Sack D.A., Harris J.R., et al. Breast feeding and the risk of severe cholera in rural Bangladeshi children. Am J Epidemiol 1990, 131:400-411.
71. Glass R.I., Svennerholm A.M., Stoll B.J., et al. Protection against cholera in breast-fed children by antibodies in breast milk. N Engl J Med 1983, 308:1389-1392.
72. Deen J., von Seidlein L., Sur D., et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis 2008, 2:e173.. doi:10.1371/journal.pntd.0000173.
73. Nalin D.R., Levine M.M., Rhead J., et al. Cannabis, hypochlorhydria, and cholera. Lancet 1978, 2:859-862.
74. Sack G.H., Pierce N.F., Hennessey K.N., et al. Gastric acidity in cholera and noncholera diarrhoea. Bull World Health Organ 1972, 47:31-36.
75. Merrell D.S., Camilli A. Acid tolerance of gastrointestinal pathogens. Curr Opin Microbiol 2002, 5:51-55.
76. van Loon F.P., Clemens J.D., Shahrier M., et al. Low gastric acid as a risk factor for cholera transmission: application of a new non-invasive gastric acid field test. J Clin Epidemiol 1990, 43:1361-1367.
77. Sircar B.K., Dutta P., De S.P., et al. ABO blood group distributions in diarrhoea cases including cholera in Calcutta. Ann Hum Biol 1981, 8:289-291.
78. Black R.E., Levine M.M., Clements M.L., et al. Association between O blood group and occurrence and severity of diarrhoea due to Escherichia coli. Trans R Soc Trop Med Hyg 1987, 81:120-123.
79. Clemens J.D., Sack D.A., Harris J.R., et al. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis 1989, 159:770-773.
80. Holmgren J., Lindblad M., Fredman P., et al. Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine. Gastroenterology 1985, 89:27-35.
81. Glass R.I., Holmgren J., Haley C.E., et al. Predisposition for cholera of individuals with O blood group: possible evolutionary significance. Am J Epidemiol 1985, 121:791-796.
82. Harris J.B., Khan A.I., LaRocque R.C., et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun 2005, 73:7422-7427.
83. Naficy A., Rao M.R., Paquet C., et al. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAMA 1998, 279:521-525.
84. Siddique A.K., Salam A., Islam M.S., et al. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma. Zaire. Lancet 1995, 345:359-361.
85. Sack D.A. Cholera vaccine in refugee settings. JAMA 1998, 280:600-602.
86. Blake P.A., Allegra D.T., Snyder J.D., et al. Cholera: a possible endemic focus in the United States. N Engl J Med 1980, 302:305-309.
87. Nalin D.R. Cholera, copepods, and chitinase. Lancet 1976, 2:958.
88. Huq A., Huq S.A., Grimes D.J., et al. Colonization of the gut of the blue crab (Callinectes sapidus) by Vibrio cholerae. Appl Environ Microbiol 1986, 52:586-588.
89. Epstein P.R. Algal blooms in the spread and persistence of cholera. Biosystems 1993, 31:209-221.
90. Islam M.S., Drasar B.S., Bradley D.J. Attachment of toxigenic Vibrio cholerae O1 to various freshwater plants and survival with a filamentous green alga, Rhizoclonium fontanum. J Trop Med Hyg 1989, 92:396-401.
91. Huq A., Small E.B., West P.A., et al. Ecological relationships between Vibrio cholerae and planktonic crustacean copepods. Appl Environ Microbiol 1983, 45:275-283.
92. Huq A., West P.A., Small E.B., et al. Influence of water temperature, salinity, and pH on survival and growth of toxigenic Vibrio cholerae serovar O1 associated with live copepods in laboratory microcosms. Appl Environ Microbiol 1984, 48:420-424.
93. Udden S.M., Zahid S.H., Biswas K., et al. Acquisition of classical CTX prophage from Vibrio cholerae 0141 by El Tor strains aided by lytic phages and chitin-induced competence. Proc Natl Acad Sci U S A 2008, 105:11951-11956.
94. Tauxe R.V., Blake P.A. Epidemic cholera in Latin America. JAMA 1992, 267:1388-1390.
95. Sack D.A. When should cholera vaccine be used in cholera-endemic areas?. J Health Popul Nutr 2003, 21:299-303.
96. Harris J., LaRocque R., Charles R., et al. Cholera's western front. Lancet 2010, 376:1961-1965.
97. Lowry P.W., Pavia A.T., McFarland L.M., et al. Cholera in Louisiana: widening spectrum of seafood vehicles. Arch Intern Med 1989, 149:2074-2084.
98. Two cases of toxigenic Vibrio cholerae O1 infection after hurricanes Katrina and Rita: Louisiana, October 2005. MMWR Morb Mortal Wkly Rep 2006, 55:31-32.
99. Steinberg E.B., Greene K.D., Bopp C.A., et al. Cholera in the United States, 1995-2000: trends at the end of the twentieth century. J Infect Dis 2001, 184:799-802.
100. DeRoeck D., Clemens J.D., Nyamete A., et al. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis, and cholera in Asia. Vaccine 2005, 23:2762-2774.
101. Bornside G.H. Waldemar Haffkine's cholera vaccines and the Ferran-Haffkine priority dispute. J Hist Med Allied Sci 1982, 37:399-422.
102. Chandrasekar C. Statistical assessment of the efficacy of anti-cholera inoculation from the data of 63 Cheris in south Sercot district. Indian J Med Res 1947, 35:153.
103. Joo I. Cholera vaccines. Cholera 1974, 333-349. WB Saunders, Philadelphia, PA. D. Barua, W. Burrows (Eds.).
104. Benenson A.S., Joseph P.R., Oseasohn R.O. Cholera vaccine field trials in east Pakistan, 1: reaction and antigenicity studies. Bull World Health Organ 1968, 38:347-357.
105. Cash R.A., Music S.I., Libonati J.P., et al. Response of man to infection with Vibrio cholerae, II: protection from illness afforded by previous disease and vaccine. J Infect Dis 1974, 130:325-333.
106. Clemens J.D., van Loon F., Sack D.A., et al. Biotype as determinant of natural immunising effect of cholera. Lancet 1991, 337:883-884.
107. Svennerholm A.M., Holmgren J. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun 1976, 13:735-740.
108. Svennerholm A.M., Jertborn M., Gothefors L., et al. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis 1984, 149:884-893.
109. Sack D.A., Clemens J.D., Huda S., et al. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis 1991, 164:407-411.
110. Kilhamn J., Brevinge H., Quiding-Jarbrink M., et al. Induction and distribution of intestinal immune responses after administration of recombinant cholera toxin B subunit in the ileal pouches of colectomized patients. Infect Immun 2001, 69:3466-3471.
111. Mosley W.H., Ahmad S., Benenson A., et al. The relationship of vibriocidal antibody titer to susceptibility of cholera in family contacts of cholera patients. Bull World Health Organ 1968, 38:777-785.
112. Clemens J., van Loon F., Sack D., et al. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis 1991, 163:1235-1242.
113. Clemens J., Stanton B., Chakraborty J., et al. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis 1987, 155:79-85.
114. Taylor D., Cardenas V., Sanchez J., et al. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 2000, 181:1667-1673.
115. Eriksson K., Kilander A., Hagberg L., et al. Intestinal antibodies to oral vaccination in HIV-infected individuals. AIDS 1993, 7:1087-1091.
116. Clemens J.D., Sack D.A., Harris J.R., et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 2:124-127.
117. van Loon F.P., Clemens J.D., Chakraborty J., et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 1996, 14:162-166.
118. Clemens J., Sack D., Harris J., et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990, 335:270-273.
119. Sanchez J.L., Vasquez B., Begue R.E., et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994, 344:1273-1276.
120. Clemens J., Sack D., Ivanoff B. Misleading negative findings in a field trial of killed, oral cholera vaccine in Peru. J Infect Dis 2001, 183:1306-1308.
121. Taylor D.N., Cárdenas V., Sanchez J.L., et al. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 2000, 181:1667-1673.
122. Lucas M.E., Deen J.L., von Seidlein L., et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005, 352:757-767.
123. Scerpella E.G., Sanchez J.L., Mathewson J.J., et al. Safety, immunogenicity, and protective efficacy of the whole-cell/recombinant B subunit (WC/rBS) oral cholera vaccine against travelers' diarrhea. J Travel Med 1995, 2:22-27.
124. Lewis D., Gilks C., Ojoo S., et al. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS 1994, 8:779-785.
125. Ortigao-de-Sampaio M., Shattock R., Hayes R., et al. Increase in plasma viral load oral cholera immunization of HIV-infected subjects. AIDS 1998, 12:F145-F150.
126. Trach D.D., Clemens J.D., Ke N.T., et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997, 349:231-235.
127. Trach D.D., Cam P.D., Ke N.T., et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull World Health Organ 2002, 80:2-8.
128. WHO Expert Committee on Biological Standardization Guidelines for the production and control of inactivated oral cholera vaccines. World Health Organ Tech Rep Ser 2004, 924:129-149.
129. Losonsky G., Lim Y., Motamedi P., et al. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae 0139: specificity and relevance to immunity. Clin Diagn Lab Immunol 1997, 4:264-269.
130. Mahalanabis D., Lopez A., Sur D., et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell cholera vaccine in adults and children in a cholera-endemic area in Kolkata, India. PLoS One 2008, 3:e2323. doi:10.1371/journal.pone.0002323.
131. Sur D., Lopez A., Kanungo A., et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1694-1702.
132. Sur D., Kanungo A., Sah B., et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow up of a randomised trial. PLoS Negl Trop Dis 2011, 5(10):e1289.
133. Anh D., Canh D., Lopez A., et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007, 25:1149-1155.
134. Kaper J.B., Levine M.M. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines. Res Microbiol 1990, 141:901-906.
135. Cryz S.J., Kaper J., Tacket C., et al. Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects. Dev Biol Stand 1995, 84:237-244.
136. Lagos R., Fasano A., Wasserman S.S., et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 1999, 180:1700-1712.
137. Tacket C.O., Cohen M.B., Wasserman S.S., et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect Immun 1999, 67:6341-6345.
138. Suharyono, Simanjuntak C., Witham N., et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992, 340:689-694.
139. Su-Arehawaratana P., Singharaj P., Taylor D.N., et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992, 165:1042-1048.
140. Tacket C.O., Losonsky G., Nataro J.P., et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992, 166:837-841.
141. Perry R., Plowe C., Koumare B., et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-non-infected adults in Mali. Bull World Health Organ 1998, 76:63-71.
142. Levine M., Kaper J., Herrington D., et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988, 1:467-470.
143. Gotuzzo E., Butron B., Seas C., et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993, 61:2994-2997.
144. Sack D.A., Tacket C.O., Cohen M.B., et al. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect Immun 1998, 66:1968-1972.
145. Heidelberg J.F., Eisen J.A., Nelson W.C., et al. DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature 2000, 406:477-483.
146. Richie E.E., Punjabi N.H., Sidharta Y.Y., et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000, 18:2399-2410.
147. Calain P., Chaine J.P., Johnson E., et al. Can oral cholera vaccination play a role in controlling a cholera outbreak?. Vaccine 2004, 22:2444-2451.
148. Cryz S.J., Levine M.M., Kaper J.B., et al. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine 1990, 8:577-580.
149. Kotloff K.L., Wasserman S.S., O'Donnell S., et al. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun 1992, 60:4430-4432.
150. Waldor M.K., Hotez P.J., Clemens J.D. A national cholera vaccine stockpile: a new humanitarian and diplomatic resource. N Engl J Med 2010, 363:2279-2282.
151. Clemens J., Spriggs D., Sack D. Public health considerations for the use of cholera vaccines in cholera control programs. Vibrio cholerae and Cholera: Molecular to Global Perspectives 1994, 425-440. American Society for Microbiology, Washington. I.K. Wachsmith, P. Blake, O. Olsvik (Eds.).
152. Ali M., Emch M., von Seidlein L., et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005, 366:44-49.
153. Ali M., Emch M., Yunus M., et al. Vaccine protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person- to-person transmission. Pediatr Infect Dis J 2008, 27:33-37.
154. Clemens J.D., Sack D.A., Rao M.R., et al. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area. J Infect Dis 1992, 166:1029-1034.
155. Longini I.M., Nizam A., Ali M., et al. Controlling endemic cholera with oral vaccines. PLoS Med 2007, 4:e336. doi:10.1371/journal.pmed.0040336.
156. Thiem V.D., Hossain M.M., Son N.D., et al. Coverage and costs of a mass immunization of an oral cholera vaccine in Vietnam. J Health Popul Nutr 2003, 21:304-308.
157. Cavailler P., Lucas M., Perroud V., et al. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. Vaccine 2006, 24:4890-4895.
158. Dorlencourt F., Legros D., Paquet C., et al. Effectiveness of mass vaccination with WC/rBS cholera vaccine during an epidemic in Adjumani district, Uganda. Bull World Health Organ 1999, 77:949-950.
159. Chaignat C-L, Monti V., Soepardi J., et al. Cholera in disasters: do vaccines prompt new hopes?. Expert Rev Vaccines 2008, 7:431-435.
160. Jeuland M., Cook J., Poulos C., et al. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health 2009, 12:899-908.
161. Committee to Advise on Tropical Medicine and Travel (CATMAT); National Advisory Committee on Immunization (NACI Statement on new oral cholera and travellers' diarrhea vaccination. Can Commun Dis Rep 2005, 31:1-11.
162. Sack D.A., Sack R.B., Shimko J., et al. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. J Infect Dis 1997, 176:201-205.
163. Cohen M.B., Giannella R.A., Bean J., et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 2002, 70:1965-1970.
164. Qadri F., Chowdhury M.K., Faruque S.M., et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 2005, 192:573-579.
165. Qadri F., Chowdhury M., Faruque S., et al. Peru-15, a live-attenuated oral cholera vaccine is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007, 25:231-238.
166. Garcia L., Jidy M.D., Garcia H., et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005, 73:3018-3024.
167. Talavera A., Ano G., Garcia H., et al. Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638. Vaccine 2006, 24:3746-3749.
168. Liu G., Yan M., Liang W., et al. Resistance of the cholera vaccine candidate IEM108 against CTXPhi infection. Vaccine 2006, 24:1749-1755.
169. Liang W., Wang S., Yu F., et al. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun 2003, 71:5498-5504.
170. Mahanalabis D., Ramamurthy T., Nair G.B., et al. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine 2009, 27:4850-4856.
171. Coster T.S., Killeen K.P., Waldor M.K., et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 1995, 345:949-952.
172. Tacket C.O., Losonsky G., Nataro J.P., et al. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis 1995, 172:883-886.
173. Ledon T., Valle E., Valmaseda T., et al. Construction and characterization of O139 cholera vaccine candidates. Vaccine 2003, 21:1282-1291.
174. Gupta R.K., Taylor D.N., Bryla D.A., et al. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect Immun 1998, 66:3095-3099.
175. Boutonnier A., Villeneuve S., Nato F., et al. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Infect Immun 2001, 69:3488-3493.
176. Kossaczka Z., Shiloach J., Johnson V., et al. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect Immun 2000, 68:5037-5043.